



GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

30th October 2024

To,

BSE LIMITED

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

Sub: Advertisement relating Financial Results

Pursuant to clause 47 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR) we enclose advertisements given in Economic Times, Business Standard and Maharashtra Times relating publication of Un-audited financial results for quarter & half year ended 30th September 2024.

Thanking you,

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

Encl: Public Notice

New & Renewable Energy Development Corporation of Andhra Pradesh Limited (NREDCAP)
(A State Government Company)
Regd. Office: #12, 46/1/1, River Oaks Apartments, CSR Kalyana Mandapam Road, Tadepalli, Guntur District, Tel: 0864277142/274133 E-Mail: gm@nredcap.in, Website: www.nredcap.in
Ref: NREDCAP/SE/Off-Grid/1/RC Rates/2024-25, Date: 30-10-2024

e-Procurement EOI NOTICE
Expression of Interest (EOI) is invited for finalization of rate contract prices for supply & installation of various Solar Off-Grid Systems under Solar Off-Grid Programme in the State of Andhra Pradesh. EOI will be available in <https://ap.eprocurement.gov.in> and NREDCAP website www.nredcap.in from 30-10-2024 at 17:00 Hrs. Ph No. 0863-2347650/651. Sd/- Dy. General Manager (T) (I/C)

JM FINANCIAL LIMITED
Corporate Identity Number: L67120MH1986PLC038784
Regd. Office: 7th Floor, Energy, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025. • Tel. No.: +91 22 6630 3030
Website: www.jmfi.com • Email: ecomunication@jmfi.com

NOTICE OF POSTAL BALLOT
NOTICE is hereby given that pursuant to the provisions of Sections 108, 110 and other applicable provisions, if any, of the Companies Act, 2013 (the "Act") read with Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014, (the "Rules"), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "SEBI Listing Regulations") and in accordance with the General Circulars Nos. 14/2020 dated April 8, 2020, 17/2020 dated April 13, 2020, and subsequent circulars issued in this regard, latest being 09/2024 dated September 19, 2024 issued by the Ministry of Corporate Affairs (the "MCA Circulars"), Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India ("SS-2") and other applicable provisions of the Act, rules, regulations, circular and notifications, including any statutory modifications and/or re-enactments thereof for the time being in force, the resolutions as set out hereunder are proposed for approval of the Members of JM Financial Limited (the "Company") by way of postal ballot through "remote e-voting".

Sr. No.	Description of Resolution	Type of Resolution
1	Re-appointment of Mr. P. S. Jayakumar (DIN: 01173236) as an Independent Director of the Company for a period of five (5) years with effect from July 30, 2025 to July 29, 2030 (both the days inclusive)	Special
2	Re-appointment of Mr. Adi Patel (DIN: 02307863) as a Managing Director of the Company for a period of three (3) years with effect from October 1, 2024 to September 30, 2027 (both the days inclusive)	Ordinary
3	Appointment of Mr. Vishal Kampani (DIN: 00009079), who is currently the Vice Chairman of the Company as its Managing Director for a period of five (5) years with effect from October 1, 2024 to September 30, 2029 (both the days inclusive)	Special

In compliance with the aforesaid provisions and the MCA Circulars, the Company has circulated the electronic copy of the Postal Ballot Notice along with the Statement pursuant to Section 102 of the Act pertaining to the aforementioned resolutions to those Members whose names appear in the Register of Members/ list of Beneficial Owners maintained by the Company/ Depositories as at close of business hours on Friday, October 18, 2024 (i.e., **Cut-off date**) and whose email addresses were registered with the Company/ Depository Participants/ Registrar and Transfer Agents i.e. KFin Technologies Limited ("RTA") as on the Cut-off date.

The copy of the Postal Ballot Notice is also made available on the website of the Company at www.jmfi.com, the websites of the stock exchanges viz., BSE Limited at www.bseindia.com and National Stock Exchange of India Limited at www.nseindia.com and on the website of National Securities Depository Limited (the "NSDL") at www.evoting.nsdl.com.

Pursuant to the provisions of the Sections 108, 110 of the Act read with Rules made thereunder, the Company is pleased to provide the facility of remote e-voting to enable its Members to cast their votes electronically in respect of all the resolutions as set out in the Postal Ballot notice. Accordingly, the Company has engaged the services of NSDL for providing e-voting facility to all its Members. Members are requested to provide their assent or dissent only through remote e-voting. Further, physical copies of the Postal Ballot Notice along with postal ballot forms and pre-paid business envelopes are not being sent to the Members for this Postal Ballot. Members are requested to provide their assent or dissent only through remote e-voting.

Information and instructions including the details of Login-id and the process for generating or receiving the password for remote e-voting are forming part of the said Postal Ballot Notice.

Members are requested to note the following important timelines:

Date of completion of dispatch of Notice	Tuesday, October 29, 2024
Commencement of remote e-voting period	Wednesday, October 30, 2024 (9.00 a.m.)
End of remote e-voting period	Thursday, November 28, 2024 (5.00 p.m.)
Cut-off date for remote e-voting	Friday, October 18, 2024

Any person whose name is recorded in the Register of Members / list of Beneficial Owners maintained by the Depositories, as on the cut-off date viz., Friday, October 18, 2024 shall only be entitled to avail the facility of remote e-voting.

The remote e-voting module shall be disabled by NSDL after 5.00 p.m. on Thursday, November 28, 2024. Once the vote on resolution is exercised and confirmed by the Member, the Members shall not be allowed to change it subsequently.

The voting rights of the Members shall be in proportion to their shares in the total paid-up equity share capital of the Company as on Cut-off date i.e. **Friday, October 18, 2024**.

Any person holding shares in physical form as on the **Cut-off date i.e., Friday, October 18, 2024**, may obtain the Login-Id and password by sending a request at evoting@nsdl.com. If Member is already registered with NSDL for remote e-voting, then he / she / it can use his / her / its existing Login Id and password for casting the votes. Password can also be reset by using "Forgot User Details/Password" or "Physical User Reset Password" option available at www.evoting.nsdl.com or call on +91 22 4886 7000.

Individual Members holding shares in demat mode may follow the steps mentioned in the notice of postal ballot under "**Access to NSDL e-voting system**".

Members who have not registered their email address yet, can register by filling Form ISR-1 and send it either to the Company at ecomunication@jmfi.com or to the RTA at inward.ris@kfinetech.com or send a physical copy of the form to the RTA at its registered office address at Selenium Building, Tower-B, Plot No 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy, Telangana India - 500 032. Members who hold shares in demat mode may contact their respective Depository Participants for updation of email address.

The Board of Directors of the Company has appointed Mr. Saurabh Agarwal (Membership No. FCS 9290), failing him Mr. Omkar Dindorkar (Membership No. ACS 43029), Designated Partners of MMJB & Associates LLP, Company Secretaries, as the scrutineer for conducting the postal ballot process through remote e-voting in a fair and transparent manner.

The results of the remote e-voting will be declared by the Chairman (or any other person authorised by Chairman) within two (2) working days from the closure of remote e-voting. The said results will be displayed at the Registered Office of the Company, placed on the Company's website viz., <https://jmfi.com/investor-relations/postal-ballot>, and will be intimated to the stock exchanges and also uploaded on the website of NSDL.

The resolutions, if passed by the requisite majority, shall be deemed to have been passed on **Thursday, November 28, 2024** i.e. the last date specified for the remote e-voting.

In case of any queries, the Members may refer frequently asked questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or may contact the authorised representative of NSDL, viz., Mr. Amit Vishal, Deputy Vice President or Mr. Sanjeev Yadav, Assistant Manager by sending a request at evoting@nsdl.com or call on +91 22 4886 7000.

Members are requested to carefully read the instructions for manner of casting their votes electronically, as stated in the Postal Ballot Notice.

For JM Financial Limited
Date: October 29, 2024
Place: Mumbai
Hemant Pandya
Company Secretary & Compliance Officer

BHAGERIA INDUSTRIES LIMITED
(CIN : L40300MH1989PLC052574)
Regd. Office: 1002, 10th Floor, Topiwala Centre, Off S.V. Road, Goregaon (W), Mumbai 400 062. Phone: +91-22-4043 6666, Fax: +91-22-4043 6662, Email id: info@bhageriagroup.com Website: www.bhageriagroup.com

EXTRACT OF THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER 30, 2024

Rs. in Lakhs (Except figures of EPS)

Sr. No.	Particulars	Standalone					Consolidated						
		For Quarter ended		For Half year ended		For Year ended	For Quarter ended		For Half year ended		For Year ended		
		30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2024 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)	30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)	
1	Total Income from operations (net)	13,265.49	11,716.54	10,610.63	24,982.03	20,716.04	51,182.03	13,241.17	11,718.10	10,610.68	24,959.26	20,716.16	51,121.13
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	878.24	831.35	395.40	1,709.59	541.33	2,735.85	844.06	803.73	380.49	1,647.79	521.77	2,626.27
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	878.24	831.35	395.40	1,709.59	541.33	2,735.85	844.06	803.73	380.49	1,647.79	521.77	2,626.27
4	"Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)"	672.69	608.84	283.28	1,281.54	412.38	1,962.40	638.51	581.23	268.37	1,219.74	392.82	1,852.82
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) & Other Comprehensive Income (after tax)]	648.02	613.72	269.33	1,261.74	400.49	1,942.92	613.76	586.10	254.42	1,199.86	380.93	1,833.34
6	Equity Share Capital	2,182.21	2,182.21	2,182.21	2,182.21	2,182.21	2,182.21	2,182.21	2,182.21	2,182.21	2,182.21	2,182.21	2,182.21
7	Reserve(excluding revaluation reserve as shown in the Balance Sheet of Previous Year)			-		-	49,765.55			-		-	50,061.50
8	Earning Per Share (Face Value of Rs.5/- each) (Not to be annualized)												
	1. Basic :	1.54	1.40	0.65	2.94	0.94	4.50	1.50	1.36	0.63	2.86	0.92	4.37
	2. Diluted :	1.54	1.40	0.65	2.94	0.94	4.50	1.50	1.36	0.63	2.86	0.92	4.37

Notes:
1. The above results have been reviewed by the Audit committee and thereafter approved by the Board of Directors at the meeting held on October 28, 2024. The Statutory Auditors have carried out the limited review.
2. The above is an extract of the detailed format of Quarterly and Half Year Ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchange website (www.bseindia.com and www.nseindia.com) and on Company's website (www.bhageriagroup.com).

For Bhageria Industries Limited
Sd/-
Suresh Bhageria
Chairman
DIN : 00540285

Date: 28.10.2024
Place: Mumbai

RP - Sanjiv Goenka Group
Growing Legacies

PCBL Limited
CIN: L23109WB1960PLC024602
Registered Office: 31, Netaji Subhas Road, Kolkata - 700001, Tele: +(91) 33 6625 1443, Fax: 033 - 2230 6844 / 2243 6681
Corporate Office: RPSG House, 2/4 Judges Court Road, 4th Floor, Kolkata - 700027, Tele: 033 24870500/600, E-mail: pcblltd@rpsg.in, Web: www.pcblltd.com

Extract of Unaudited Standalone and Consolidated Financial Results for the Quarter and Six Months ended 30th September, 2024 (₹ In Crores except as otherwise stated)

Sl. No.	Particulars	Standalone				Consolidated			
		3 Months ended	6 Months ended	Corresponding 3 Months ended	Year ended	3 Months ended	6 Months ended	Corresponding 3 Months ended	Year ended
		30.09.2024	30.09.2024	30.09.2023	31.03.2024	30.09.2024	30.09.2024	30.09.2023	31.03.2024
1	Total Income from operations	1,538.46	3,036.73	1,399.67	5,705.30	2,168.85	4,323.29	1,489.39	6,456.80
2	Net Profit / (Loss) for the period (before tax and exceptional items)	167.84	331.96	181.12	720.81	163.83	327.40	171.59	676.33
3	Net Profit / (Loss) for the period before tax (after exceptional items)	167.84	331.96	181.12	720.81	163.83	327.40	171.59	676.33
4	Net Profit / (Loss) for the period after tax (after exceptional items)	129.04	245.32	132.36	533.29	123.45	241.37	122.83	491.11
5	Total comprehensive income for the period	273.60	455.80	169.04	667.19	268.27	454.85	158.39	623.88
6	Paid-up Equity Share Capital (Shares of ₹ 1/- each)	37.75	37.75	37.75	37.75	37.75	37.75	37.75	37.75
7	Reserves (excluding Revaluation Reserves as shown in the Audited Balance Sheet of the previous year)	3,241.46	3,241.46	2,781.87	3,241.46	3,208.94	3,208.94	2,792.42	3,208.94
8	Securities Premium Account	610.95	610.95	610.95	610.95	610.95	610.95	610.95	610.95
9	Net worth	3,238.67	3,238.67	2,789.26	2,994.41	3,193.71	3,193.71	2,921.97	2,953.51
10	Paid up Debt Capital/Outstanding Debt	700.00	700.00	-	700.00	1,250.00	1,250.00	-	1,250.00
11	Outstanding Redeemable Preference Shares	-	-	-	-	-	-	-	-
12	Debt Equity Ratio	0.71	0.71	0.22	0.87	1.25	1.25	0.32	1.48
13	Earnings Per Share (EPS) (Face Value of ₹ 1/- each) (*not annualised): Basic	3.42*	6.50*	3.51*	14.13	3.27*	6.39*	3.25*	13.00
14	Earnings Per Share (EPS) (Face Value of ₹ 1/- each) (*not annualised): Diluted	3.41*#	6.49*#	3.51*	14.13	3.26*#	6.38*#	3.25*	13.00
15	Capital Redemption Reserve	-	-	-	-	-	-	-	-
16	Debt Redemption Reserve	-	-	-	-	-	-	-	-
17	Debt Service Coverage Ratio	1.87	2.05	4.21	3.63	3.05	2.56	4.21	2.8
18	Interest Service Coverage Ratio	4.38	3.98	32.61	9.98	2.82	2.67	40.81	6.71

(# after considering impact of share warrants.)

Notes:
a) The above is an extract of the detailed format of the Unaudited Standalone and Consolidated Financial Results for the quarter and six months ended 30th September, 2024 filed with the Stock Exchanges under Regulations 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the aforesaid Results for the quarter and six months ended 30th September, 2024 are available on the Company's website (www.pcblltd.com) and on the websites of the National Stock Exchange of India Limited (NSE) (www.nseindia.com) and BSE Limited (BSE) (www.bseindia.com).

By Order of the Board
Kaushik Roy
Managing Director
DIN : 06513489

Place : Kolkata
Date : 29th October, 2024

GSK **GlaxoSmithKline Pharmaceuticals Limited**
Registered Office: Dr. Annie Besant Road, Mumbai 400030 • Website: www.gsk-india.com
Email: askus@gsk.com • Corporate Identity Number: L24239MH1924PLC001151

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30TH SEPTEMBER, 2024 (₹ in Lakhs)

Particulars	Standalone						Consolidated						
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)		
	3 months ended 30.09.2024	Preceding 3 months ended 30.06.2024	Corresponding 3 months ended 30.09.2023	6 months ended 30.09.2024	6 months ended 30.09.2023	Year ended 31.03.2024	3 months ended 30.09.2024	Preceding 3 months ended 30.06.2024	Corresponding 3 months ended 30.09.2023	6 months ended 30.09.2024	6 months ended 30.09.2023	Year ended 31.03.2024	
1	Revenue from continuing operations	100005	81100	95338	181105	169140	340725	101077	81465	95699	182542	171865	345371
2	Profit before Exceptional Items and tax	33401	24849	29651	58250	45792	95265	33912	24940	29916	58852	46284	95980
3	Exceptional Items [credit / (charge)]	469	-	-	469	1730	(14361)	469	-	-	469	1730	(14361)
4	Profit before tax	33870	24849	29651	58719	47522	80904	34381	24940	29916	59321	48014	81619
5	Net Profit after tax	24869	18165	21554	43034	34612	58469	25250	18233	21751	43483	34976	58996
6	Total comprehensive income for the period	24869	18165	21554	43034	34612	58052	25250	18233	21751	43483	34976	58579
7	Paid-up Equity Share Capital (Face value per share ₹ 10)	16941	16941	16941	16941	16941	16941	16941	16941	16941	16941	16941	16941
8	Other Equity	-	-	-	-	-	161468	-	-	-	-	-	160823
9	Earnings Per Share (EPS) (of ₹ 10 each) (for continuing and discontinued operations)												
	Basic and diluted EPS before Exceptional Items (₹)	14.45	10.72	12.72	25.17	19.66	40.83	14.67	10.76	12.84	25.43	19.88	41.14
	Basic and diluted EPS after Exceptional Items (₹)	14.68	10.72	12.72	25.40	20.43	34.51	14.91	10.76	12.84	25.67	20.65	34.83
		Not Annualised						Not Annualised					

Notes:
1. The above is an extract of the detailed format of the Financial Results for the quarter and six months ended September 30, 2024 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the website of the Company at www.gsk-india.com and on the website of Stock Exchanges at www.nseindia.com and www.bseindia.com.
2. The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 29th October, 2024.
3. The Board of Directors at their meeting held on 29th October 2024 declared a special interim dividend of Rs. 12 per equity share of face value of Rs. 10 each.

By Order of the Board
Bhushan Akshikar
Managing Director
DIN: 09112346

Place: Mumbai
Date: 29th October, 2024

Suven Pharma's Casper Merger Gets NCLT Nod

Suven Pharma had acquired CPPL in April 2022 for about ₹155 cr

Maulik Vyas

Mumbai: The Mumbai bench of the National Company Law Tribunal (NCLT) has approved Casper Pharma's merger with listed drug maker, Suven Pharmaceuticals.

In April 2022, Suven Pharmaceuticals acquired Casper Pharma (CPPL) for about ₹155 crore. Casper Pharma had an installed capacity of 120 crore tablets and capsules at the time of the acquisition by Suven Pharmaceuticals.

The scheme of amalgamation (merger) is expected to create greater efficiency due to the consolidation of operations, pooling and more effective utilisation of the companies' combined resources, reduction in overheads, costs and expenses, economies of scale, elimination of duplication of work and rationalization and reduction of compliance requirements.

"From the material on record, the scheme appears to be fair and reasonable and does not violate any provisions of law and is not contrary to public policy," observed the division bench of Justice VG Bisht

and a technical member Prabhath Kumar in its order, while allowing the scheme of amalgamation in its order of October 24.

Before the tribunal's order, Meghna Rajadhyaksha of law firm Shardul Amarchand Mangaldas & Co, appeared for the companies and informed the tribunal that the proposed amalgamation of the transferor company (Casper Pharma) with the transferee company (Suven Pharmaceuticals) will create concentrated management focus and integration with uniform management procedures and seamless implementation of policy changes.

Ankita Singh, managing partner of Sarvaank Associates, said that the approval of the amalgamation scheme between Casper Pharma and Suven Pharmaceuticals is a significant milestone in creating a more efficient corporate structure.

"By integrating Casper's assets and expertise, Suven aims to optimize costs and tap into new revenue streams, thereby strengthening its competitive position in the pharmaceutical industry," adds Singh. "As part of the amalgamation scheme, Suven Pharma has the option to exercise approximately 6.59 million employee stock options from Casper, which will help keep key talent engaged and invested in the company's future," she added.

The companies, through their counsel, also argued that the amalgamation will create a streamlined group structure which will assist in more efficient utilisation of capital.

Healthy Deal

CPPL had an installed capacity of 120-crore tablets during deal

Suven gets option to use 6.59 m employee stock options

Suven aims to cut costs and tap into new revenue streams

From the material on record, the scheme appears to be fair and reasonable and does not violate any provisions of law and is not contrary to public policy," observed the division bench of Justice VG Bisht

Delhi High Court Orders Auction of Fortis Trademark

NEW DELHI The Delhi High Court on Tuesday ordered auctioning of the Fortis trademark in connection with the ₹3,500 crore arbitral award passed in favour of Japanese pharmaceutical major Daiichi Sankyo and against the former Ranbaxy promoters.

Justice Sachin Datta passed the order on an application filed by Daiichi Sankyo seeking the sale of the Fortis trademark, owned by RHC Healthcare Management Services which is one of the judgment debtors in the matter.

The petition was filed by Daiichi Sankyo seeking execution of a ₹3,500-crore Singapore tribunal arbitral award passed in its favour and against former promoters of Fortis Healthcare, in April 2016.

The competition watchdog CCI on Tuesday approved Fortis Healthcare's proposal to acquire an additional 31.5% stake in Agilus Diagnostics. PTI

Services which is one of the judgment debtors in the matter.

The petition was filed by Daiichi Sankyo seeking execution of a ₹3,500-crore Singapore tribunal arbitral award passed in its favour and against former promoters of Fortis Healthcare, in April 2016.

The competition watchdog CCI on Tuesday approved Fortis Healthcare's proposal to acquire an additional 31.5% stake in Agilus Diagnostics. PTI

Torrent Plea Against Sarada Bid SC Seeks Reply on SKS Power Resolution Plan

Indu Bhan

New Delhi: The Supreme Court had sought responses from debt-ridden SKS Power Generation (Chhattisgarh), its lenders and its resolution professional on an appeal by Torrent Power challenging the approval granted to Sarada Energy and Minerals' resolution plan for takeover of the power generation firm.

A bench led by chief justice D Y Chandrachud, while issuing notice to SKS, its committee of creditors and resolution professional Ashish Arjankumar Rathi and Sarada Energy, the successful resolution applicant, observed that "there is much more than what meets the eye."

The court noted senior counsel AM Singhvi's submission on behalf of Torrent that Sarada's bid was modified in material respects after the conclusion of the negotiation process.

The CJI directed that "any further steps which are taken in implementation of the resolution plan by the second respondent (Sarada) shall not create any equities in their favour." The bench posted the matter for further hearing on November 12.

Torrent has told the SC that Sarada had selectively been allowed to revise its commercial offer (by two deviations at the very least) in a "surreptitious and clandestine manner" after the conclusion of the negotiation process and the disclosure of the final bid to all re-

Under Lens

Torrent has told the SC that Sarada had selectively been allowed to revise its offer

CJI says that by any further implementation of resolution plan, Sarada shall not create any equities in its favour

SC posted the matter for further hearing on Nov 12

solution applicants.

"The selection of the successful resolution applicant by the resolution professional and CoC has been done in complete disregard to the settled principles of fairness, transparency and level-playing field," the Ahmedabad-based company alleged, adding that discrimination was made towards other resolution applicants as Sarada was given an opportunity in the guise of seeking clarification to pay ₹240 crore upfront payment, which was not proposed earlier.

Sarada was also allowed to modify/increase amount of infusion of funds towards replacement margin money relating to bank guarantees from ₹103.8 crore to ₹180 crore, after the closure of the Negotiation Process, it alleged. Singapore-based Vantage Point Asset Management Pte's appeal on the same issue is yet to be heard by the SC.

NOCIL LIMITED													
Regd. Office : Mafatal House, 3rd Floor, H. T. Parekh Marg, Backbay Reclamation, Churchgate, Mumbai - 400 020, India. Website : www.nocil.com, Email : investorcare@nocil.com, CIN : L99999MH1961PLC012003													
EXTRACT OF STANDALONE & CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR AND QUARTER ENDED 30 SEPTEMBER, 2024													
Sr. No.	Particulars	Standalone					Consolidated						
		For the Quarter ended on		For the Six Months ended on		For the year ended on	For the Quarter ended on		For the Six Months ended on		For the year ended on		
		30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2024 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)	30.09.2024 (Unaudited)	30.06.2024 (Unaudited)	30.09.2023 (Unaudited)	30.09.2024 (Unaudited)	30.09.2023 (Unaudited)	31.03.2024 (Audited)
1	Total Income from Operations	362.70	372.17	350.88	734.87	747.55	1,444.67	362.70	372.17	350.88	734.87	747.55	1,444.67
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	32.38	36.43	35.95	68.81	82.06	177.14	32.33	36.76	36.53	69.09	83.69	179.99
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	32.38	36.43	35.95	68.81	82.06	177.14	32.33	36.76	36.53	69.09	83.69	179.99
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	41.46	27.23	26.87	68.69	60.45	131.35	42.13	27.06	27.16	69.19	61.46	133.00
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	12.51	105.06	96.44	117.57	146.98	193.86	13.15	104.84	96.85	117.99	148.05	195.63
6	Equity Share Capital	166.90	166.65	166.65	166.90	166.65	166.65	166.90	166.65	166.65	166.90	166.65	166.65
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	-	-	-	-	-	-	1,531.93
8	Earnings Per Share (of ₹ 10/- each) (for continuing and discontinued operations) -												
	1. Basic :	2.49	1.63	1.62	4.12	3.63	7.88	2.53	1.62	1.63	4.15	3.69	7.98
	2. Diluted :	2.48	1.63	1.61	4.11	3.62	7.85	2.52	1.62	1.63	4.14	3.68	7.95

Notes:

- The above unaudited results, as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at their meeting held on 28th October, 2024
- The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results is available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.nocil.com.

For and on behalf of the Board,
Anand V.S.
Managing Director
DIN : 07918665

Place : Mumbai
Date : 28th October 2024

GSK GlaxoSmithKline Pharmaceuticals Limited													
Registered Office: Dr. Annie Besant Road, Mumbai 400030 • Website: www.gsk-india.com Email: askus@gsk.com • Corporate Identity Number: L24239MH1924PLC001151													
STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30 TH SEPTEMBER, 2024													
Particulars	Standalone						Consolidated						
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
	3 months ended 30.09.2024	Preceding 3 months ended 30.06.2024	Corresponding 3 months ended 30.09.2023	6 months ended 30.09.2024	6 months ended 30.09.2023	Year ended 31.03.2024	3 months ended 30.09.2024	Preceding 3 months ended 30.06.2024	Corresponding 3 months ended 30.09.2023	6 months ended 30.09.2024	6 months ended 30.09.2023	Year ended 31.03.2024	
1	Revenue from continuing operations	100005	81100	95338	181105	169140	340725	101077	81465	95699	182542	171865	345371
2	Profit before Exceptional Items and tax	33401	24849	29651	58250	45792	95265	33912	24940	29916	58852	46284	95980
3	Exceptional Items [credit / (charge)]	469	-	-	469	1730	(14361)	469	-	-	469	1730	(14361)
4	Profit before tax	33870	24849	29651	58719	47522	80904	34381	24940	29916	59321	48014	81619
5	Net Profit after tax	24869	18165	21554	43034	34612	58469	25250	18233	21751	43483	34976	58996
6	Total comprehensive income for the period	24869	18165	21554	43034	34612	58052	25250	18233	21751	43483	34976	58579
7	Paid-up Equity Share Capital (Face value per share ₹ 10)	16941	16941	16941	16941	16941	16941	16941	16941	16941	16941	16941	16941
8	Other Equity	-	-	-	-	-	161468	-	-	-	-	-	160823
9	Earnings Per Share (EPS) (of ₹ 10 each) (for continuing and discontinued operations)												
	Basic and diluted EPS before Exceptional Items (₹)	14.45	10.72	12.72	25.17	19.66	40.83	14.67	10.76	12.84	25.43	19.88	41.14
	Basic and diluted EPS after Exceptional Items (₹)	14.68	10.72	12.72	25.40	20.43	34.51	14.91	10.76	12.84	25.67	20.65	34.83

Notes:

- The above is an extract of the detailed format of the Financial Results for the quarter and six months ended September 30, 2024 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Financial Results are available on the website of the Company at www.gsk-india.com and on the website of Stock Exchanges at www.nseindia.com and www.bseindia.com.
- The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 29th October, 2024.
- The Board of Directors at their meeting held on 29th October 2024 declared a special interim dividend of Rs. 12 per equity share of face value of Rs. 10 each.

By Order of the Board
Bhushan Akshikar
Managing Director
DIN: 09112346

Place: Mumbai
Date: 29th October, 2024

With NavBharat Times you reach out to its 87% of NCCS A readers.

To ensure your client's next model is on their radar, make NBT a part of your media plan.

PRAGATI KA PARTNER

Call us at 1800 1205474

www.nbt.in | Facebook: /navbharattimes | X: @NavbharatTimes

Source: As per study conducted by AIKIU among newspaper readers of a sample size of 2502 across Delhi NCR in September 2023. Reach out to us on: timesresponse@timesofindia.com

बलात्कारास तीन वर्षांनंतर फुटली वाचा

म. टा. वृत्तसेवा, नवी मुंबई

वाराहीत राहणाऱ्या एका अल्पवयीन मुलीवर तिच्या काकाने लैंगिक अत्याचार केल्याचा प्रकार उघडकीस आला आहे. पीडित मुलीने याबाबतची माहिती शाळेतून शिक्षिकेला दिल्यानंतर शिक्षिकेने स्वतः पोलिस ठाण्यात तक्रार दाखल केली. त्यानुसार पोलिसांनी आरोपीवर बलात्कारासह पोक्सो कलमानुसार गुन्हा दाखल करून त्याचा शोध सुरू केला आहे. ही मुलगी इयत्ता नववीत शिकत आहे. २०२२मध्ये ही

पीडित मुलगी कुटुंबीयांसह काकाच्या घरी गेली होती. यावेळी काकाने मध्यरात्रीच्या सुमारास तिच्यावर बलात्कार केला होता. मात्र घाबरून तिने या प्रकारची माहिती कोणालाही दिली नाही. मात्र गेल्या आठवड्यात ही मुलगी शाळेत गेली असता शिक्षिकेकडून सर्व मुलींना लैंगिक शोषणाबाबत माहिती देण्यात आली. त्यानंतर पीडित मुलीने तिच्यावर तीन वर्षांपूर्वी झालेल्या प्रकाराबाबत माहिती दिली. त्यानंतर या शिक्षिकेने पोलिस ठाण्यात जाऊन याबाबत तक्रार नोंदवली.

प्रेमप्रकरणास नकार दिल्याने तरुणीची हत्या

म. टा. प्रतिनिधी, ठाणे

प्रेमप्रकरणास नकार देणाऱ्या तरुणीची तिच्या घरातच चाकूने वार करून हत्या केल्याचा भिडंडीतील भादवड परिसरात घडला. या तरुणीला वाचवण्यासाठी गेलेल्या तिच्या लहान बहिणीवरही आरोपीने चाकूने हल्ला केला. यामध्ये ती जखमी झाली आहे. राजू सिंह (२४) असे या आरोपीचे नाव असून, तो फरार आहे. या प्रकरणी शांतीनगर पोलिस ठाण्यात गुन्हा दाखल झाला आहे. भादवड परिसरात राजू राहतो. तर, मृत २३ वर्षांची तरुणी याच भागात राहत होती. त्यांचे उत्तर प्रदेशमधील गावही एकच आहे. तरुणीने राजूला प्रेमप्रकरणास नकार दिला होता.

भिडंडीतील भादवड परिसरातील घटना

याच रागातून राजू हा सोमवारी सकाळी तरुणीच्या घरी आला. त्याने भाजी कापण्याच्या सुचाने तरुणीवर वार केले. या हल्ल्यात गंभीर जखमी झालेल्या तरुणीला रुग्णालयात नेण्यात आले. मात्र, तिचा मृत्यू झाला होता. तरुणीला वाचवण्यासाठी तिच्या १६ वर्षांच्या बहिणीने धाव घेतली असता, आरोपीने तिच्यावरही चाकूने हल्ला केला. पोलिसांकडून आरोपीचा शोध घेण्यात येत आहे. आरोपी हा बांधकाम व्यावसायिकाकडे सुरक्षाक्षकाची नोकरी करत असल्याची माहिती पोलिसांनी दिली.

विशेष रेल्वे अचानक रद्द

म. टा. प्रतिनिधी, छत्रपती संभाजीनगर

ऐन दिवाळीच्या काळात पुण्याहून मराठवाड्यात येणारी विशेष रेल्वे नोंदेड रेल्वे विभागाने रद्द केले. दिवाळीच्या पूर्वेसध्याला ही रेल्वे रद्द झाल्याने या रेल्वेतून प्रवास करणाऱ्या प्रवाशांचे मराठवाड्याकडे येण्यासाठी हाल होणार आहेत.

पुण्याहून मराठवाड्याकडे जाणाऱ्या प्रवाशांचे हाल



हे कारण...

पुण्याहून ही रेल्वे वॉटिंगवर आहे. ही वाव बरोबर आहे. मात्र ही रेल्वे नोंदेडहून पुण्याला जात असताना ही रेल्वे दहा टक्केही भरत नाही. यामुळे येणाऱ्या प्रवाशांचा विचार न करता, ही रेल्वे रद्द करण्यात आली असल्याची प्रतिक्रिया संघटनांनी दिली.

पोहोचली होती. याशिवाय २९ ऑक्टोबर रोजी थर्ड एसीमध्ये ७६ जागा उपलब्ध होत्या. याशिवाय ३१ ऑक्टोबर रोजी थर्ड एसीची प्रतीक्षा यादी १२व आली होती. दिवाळीपूर्वी प्रतीक्षा यादीतील तिकीट कमी झाल्याने उर्वरित सर्व तिकीट घेणाऱ्या प्रवाशांना कन्फर्म तिकीट मिळाले होते. मात्र २७ ऑक्टोबरला सदर रेल्वे प्रतीक्षा यादीत असतानाही ही रेल्वे रद्द करण्यात आल्याचे घोषित करण्यात आले.

तेरा लाख प्रौढांना बीसीजी लस

म. टा. प्रतिनिधी, पुणे

क्षयरोग प्रतिबंधासाठी राज्यात बीसीजी लसीकरण मोहीम राबविण्यात येत असून, आतापर्यंत १३ लाख नागरिकांनी बीसीजी लस घेतली आहे. बीसीजी लस क्षयरोगावर प्रभावी आहे का? हे या मोहिमेतून समोर येणार आहे. यामुळे राज्यातील सुमारे १७ लाख नागरिकांचे लसीकरण करण्याचे लक्ष्य आरोग्य विभागाने ठेवले आहे. लसीकरण मोहीम डिसेंबरच्या पहिल्या आठवड्यापर्यंत सुरू राहणार असल्याचे आरोग्य विभागाने स्पष्ट केले.

आले आहे. मात्र, १८ वर्षांवरील नागरिकांना क्षयरोग होऊ नये म्हणून बीसीजी उपयोगी पडते का? याचा अभ्यास करण्यासाठी ही मोहीम राबविली जात आहे. लसीकरणाने संकलित होणाऱ्या माहितीचा अभ्यास आयसीएमआर, केंद्रीय क्षयरोग विभाग आणि राज्य आरोग्य विभाग करणार आहे. राज्यात सप्टेंबरपासून लसीकरण मोहीम सुरू झाली आहे. पुण्यासह १६ जिल्हे आणि १२ महापालिकांमध्ये लसीकरण मोहीम राबविण्यात येत आहे. राज्यातील १७ लाख नागरिकांना लस देण्याचे लक्ष्य आरोग्य विभागाने ठेवले आहे.

सरकारी रुग्णालयांमध्ये ही लस देण्यात येत आहे. लसीकरणामध्ये बीसीजी लसीची एक मात्र देण्यात येत असून लस देण्याआधी संबंधित व्यक्तीची संमती घेतली जात असल्याचेही आरोग्य विभागाने स्पष्ट केले आहे. राज्यात मोहीम राबविण्यापूर्वी सर्वेक्षण करण्यात आले होते. या सर्वेक्षणात क्षयरोगाचा धोका असलेल्या नागरिकांचा शोध घेण्यात आला होता.

विजय पालांडेला जामीन नाहीच

मुंबई : दिल्लीस्थित व्यावसायिक अरुण टिक्कू यांची २०१२मध्ये अंधेरी येथे हत्या केल्याचा प्रकरणात कुख्यात

गुंड विजय पालांडे याला जामीन देण्यास मुंबई सत्र न्यायालयाने नुकताच नकार दिला.

पालांडेविरोधात अनेक गुन्हाप्रकरणी खटले सुरू आहेत. त्याला अरुण टिक्कू च चित्रपट निर्माते करणकुमार कक्कड यांच्या हत्यांच्या प्रकरणात एप्रिल-२०१२मध्ये अटक करण्यात आली. त्याशिवाय आरोपींना यापूर्वीच जामीन मिळाला आहे आणि खटला प्रलंबित असूनही तुरुंगवास प्रदीर्घ काळ झाला आहे, या कारणांखाली पालांडेने अर्जाद्वारे जामीन मिळण्याची विनंती केली होती. मात्र, 'तो अन्य गुन्हात शिक्षाही भोगत आहे', असा युक्तिवाद विशेष सरकारी वकील उज्वल निकम यांनी सत्र न्यायालयाने प्रथम न्यायाधीश ए. सुब्रमण्यम यांच्यासमोर मांडला.

अनु. क्र.		तपशील	एकल (STANDALONE)						एकत्रित (CONSOLIDATED)					
			संपलेल्या तिमाही करिता		संपलेल्या सहा महिन्यांकरिता		संपलेल्या वर्षाकरिता		संपलेल्या तिमाही करिता		संपलेल्या सहा महिन्यांकरिता		संपलेल्या वर्षाकरिता	
			३०.०९.२०२४ (अलेखापरिहित)	३०.०६.२०२४ (अलेखापरिहित)	३०.०९.२०२३ (अलेखापरिहित)	३०.०९.२०२४ (अलेखापरिहित)	३०.०९.२०२३ (अलेखापरिहित)	३१.०३.२०२४ (लेखापरिहित)	३०.०९.२०२४ (अलेखापरिहित)	३०.०६.२०२४ (अलेखापरिहित)	३०.०९.२०२३ (अलेखापरिहित)	३०.०९.२०२४ (अलेखापरिहित)	३१.०३.२०२४ (लेखापरिहित)	
१	प्रचलनातून एकूण उत्पन्न	३६२.७०	३७२.१७	३५०.८८	७३४.८७	७४७.५५	१,४४४.६७	३६२.७०	३७२.१७	३५०.८८	७३४.८७	७४७.५५	१,४४४.६७	
२	कालावधीकरिता निव्वळ नफा / (तोटा) (कर, अपवादालात्मक आणि / किंवा असाधारण बाबीपूर्वी)	३२.३८	३६.४३	३५.९५	६८.८१	८२.०६	१७७.१४	३२.३३	३६.७६	३६.५३	६९.०९	८३.६९	१७९.९९	
३	करापूर्वी कालावधीकरिता निव्वळ नफा / (तोटा) (अपवादालात्मक आणि / किंवा असाधारण बाबीनंतर)	३२.३८	३६.४३	३५.९५	६८.८१	८२.०६	१७७.१४	३२.३३	३६.७६	३६.५३	६९.०९	८३.६९	१७९.९९	
४	करा नंतर कालावधीकरिता निव्वळ नफा / (तोटा) (अपवादालात्मक आणि / किंवा असाधारण बाबीनंतर)	४१.४६	२७.२३	२६.८७	६८.६९	६०.४५	१३१.३५	४२.१३	२७.०६	२७.१६	६९.१९	६९.४६	१३३.००	
५	कालावधीकरिता एकूण व्यापक उत्पन्न [कालावधीकरिता नफा / (तोटा) (करा नंतर) आणि इतर व्यापक उत्पन्न (करा नंतर) समाविष्ट]	१२.५१	१०५.०६	९६.४४	११७.५७	१४६.९८	१९३.८६	१३.१५	१०४.८४	९६.८५	११७.९९	१४८.०५	१९५.६३	
६	इक्विटी भाग भांडवल	१६६.९०	१६६.६५	१६६.६५	१६६.९०	१६६.६५	१६६.६५	१६६.९०	१६६.६५	१६६.६५	१६६.९०	१६६.६५	१६६.६५	
७	मागिल वर्षाच्या लेखापरिहित ताळेबंदात दर्शविल्याप्रमाणे राखीव (पुनर्मुल्यांकन राखीव वगळता)	-	-	-	-	-	-	-	-	-	-	-	-	
८	प्रती भाग मिळकत (₹ १०/- प्रत्येकी) (चालू आणि खंडित प्रचलनाकरिता) -	२.४९	१.६३	१.६२	४.१२	३.६३	७.८८	२.५३	१.६२	१.६३	४.१५	३.६९	७.९८	
९	वैसिक :	२.४८	१.६३	१.६१	४.११	३.६२	७.८५	२.५२	१.६२	१.६३	४.१४	३.६८	७.९५	
१०	१. 'खाल्युटेड' :													

सूचना : १ उपरोक्त अलेखापरिहित निष्कर्ष, न्याचा लेखापरिषद समितीद्वारा आढावा घेतला तसेच संचालक मंडळाद्वारा २८ ऑक्टोबर, २०२४ रोजी झालेल्या त्यांच्या बैठकीत विचार केला गेला, मान्यता दिली आणि रेकॉर्डवर घेतले. २ उपरोक्त, सेबी (लिस्टिंग ऑब्लिगेशन्स अँड डिस्कलोनर रिक्वायर्मेंट्स) रेग्युलेशन्स, २०१५ च्या रेग्युलेशन्स ३३ अंतर्गत स्टॉक एक्सचेंजसह दाखल केलेल्या वित्तीय निष्कर्षांच्या विस्तृत स्वरूपाचे अर्क आहे. वित्तीय निष्कर्षांचे संपूर्ण स्वरूप स्टॉक एक्सचेंजची वेबसाइट www.nseindia.com आणि www.bseindia.com आणि तसेच कंपनीची वेबसाइट www.nocil.com वर उपलब्ध आहेत.

GSK वॉल्क्सो रिमथक्लाइन फार्मास्युटिकल्स लिमिटेड

नोंदणीकृत कार्यालय : डॉ. अॅनी बेझंट रोड, मुंबई ४०००३० • वेबसाइट : www.gsk-india.com
ई मेल : askus@gsk.com • कॉर्पोरेट आयडेंटिटी क्रमांक : L24239MH1924PLC001151
३० सप्टेंबर, २०२४ ला संपलेल्या तिमाही आणि सहा महिन्यांकरिता एकल (Standalone) आणि एकत्रित अलेखापरिहित वित्तीय निष्कर्षांचे विवरण (₹ लाखात)

तपशील	एकल (Standalone)						एकत्रित					
	३०.०९.२०२४ ला संपलेले तीन महिने		३०.०६.२०२४ ला संपलेले सहा महिने		३०.०९.२०२३ ला संपलेले तीन महिने		३०.०९.२०२४ ला संपलेले ६ महिने		३१.०३.२०२४ ला संपलेले ६ महिने		३१.०३.२०२४ ला संपलेले वर्ष	
	(अलेखापरिहित)	(अलेखापरिहित)	(अलेखापरिहित)	(अलेखापरिहित)	(अलेखापरिहित)	(लेखापरिहित)	(अलेखापरिहित)	(अलेखापरिहित)	(अलेखापरिहित)	(अलेखापरिहित)	(अलेखापरिहित)	(लेखापरिहित)
१ चालू प्रचलनातून महत्त्व	100005	81100	95338	181105	169140	340725	101077	81465	95699	182542	171865	345371
२ अपवादालात्मक बाबी पूर्वी नफा आणि कर	33401	24849	29651	58250	45792	95265	33912	24940	29916	58852	46284	95980
३ अपवादालात्मक बाबी [परा/ (शुल्क)]	469	-	-	469	1730	(14361)	469	-	-	469	1730	(14361)
४ करा पूर्वी नफा	33870	24849	29651	58719	47522	80904	34381	24940	29916	59321	48014	81619
५ करा नंतर निव्वळ नफा	24869	18165	21554	43034	34612	58469	25250	18233	21751	43483	34976	58996
६ कालावधीकरिता एकूण व्यापक उत्पन्न	24869	18165	21554	43034	34612	58052	25250	18233	21751	43483	34976	58579
७ भारणा केलेले समभाग भांडवल (दर्शनी मूल्य प्रती भाग ₹ १०)	16941	16941	16941	16941	16941	16941	16941	16941	16941	16941	16941	16941
८ इतर इक्विटी	-	-	-	-	-	161468	-	-	-	-	-	160823
९ प्रति भाग मिळकत (₹ प्रती) (₹ १० प्रत्येकी) (चालू आणि खंडित प्रचलनासाठी)	14.45	10.72	12.72	25.17	19.66	40.83	14.67	10.76	12.84	25.43	19.88	41.14
अपवादालात्मक बाबीपूर्वी वैसिक आणि डायव्हिडेंड ईपीएस (₹)	14.45	10.72	12.72	25.17	19.66	40.83	14.67	10.76	12.84	25.43	19.88	41.14
अपवादालात्मक बाबीनंतर वैसिक आणि डायव्हिडेंड ईपीएस (₹)	14.68	10.72	12.72	25.40	20.43	34.51	14.91	10.76	12.84	25.67	20.65	34.83
	वार्षिक नाही						वार्षिक नाही					

सूचना : १ उपरोक्त हे ३० सप्टेंबर, २०२४ ला संपलेल्या तिमाही आणि सहा महिन्यांसाठी सेबी (लिस्टिंग ऑब्लिगेशन्स अँड डिस्कलोनर रिक्वायर्मेंट्स) रेग्युलेशन्स, २०१५ च्या रेग्युलेशन्स ३३ अंतर्गत स्टॉक एक्सचेंजसह सोबत फाईल केलेल्या वित्तीय निष्कर्षांच्या तपशीलवार स्वरूपाचा सारांश आहे. उक्त वित्तीय निष्कर्षांचे संपूर्ण स्वरूप कंपनीची वेबसाइट www.gsk-india.com येथे आणि स्टॉक एक्सचेंजेसव्ची वेबसाइट www.nseindia.com आणि www.bseindia.com येथे उपलब्ध आहेत. २ उपरोक्त निष्कर्षांचा लेखा समितीने आढावा घेतला आणि २९ ऑक्टोबर, २०२४ रोजी झालेल्या त्यांच्या संबंधित बैठकीत संचालक मंडळाद्वारे त्यानंतर मान्यता देण्यात आली आहे. ३ संचालक मंडळाने २९ ऑक्टोबर, २०२४ रोजी झालेल्या त्यांच्या बैठकीत प्रत्येकी रु. १० च्या दर्शनी मूल्याच्या प्रति इक्विटी शेअरवर रु. १२ चा विशेष अंतरिम लाभांश जाहीर केला आहे.

ठिकाण : मुंबई
दिनांक : २९ ऑक्टोबर, २०२४

LET OUR READERS TAKE YOU ON A JOURNEY OF SUCCESS!

33% of Maharashtra Times readers in Mumbai and 31% in Pune intend to purchase a high-end car in the next year.

Contact your Times Response Associate now to advertise with us.

Source - As per study conducted amongst newspaper readers. Sample Size of 1572 in Dec'23

maharashtratimes.com | t.me/mataonline | facebook.com/maharashtratimesonline